Benjamin F. Edwards & Company, Inc. Hepion Pharmaceuticals, Inc. Call Options Transaction History

Benjamin F. Edwards & Company, Inc.

  • $5.69 Billion
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Hepion Pharmaceuticals, Inc.

HEPA Quotes by TradingView
  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $49.5M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email